Transgenomic, Raptor to Collaborate
News Apr 04, 2014
Transgenomic, Inc. announce an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor’s clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.
Leigh syndrome is a severe neurological disorder that typically arises in the first year of life. This condition is characterized by progressive loss of mental and movement abilities (psychomotor regression) and typically results in death within a few years, usually due to respiratory failure.
“We look forward to working with Raptor and the study investigators, using our leading-edge mitochondrial genetic testing capabilities to uncover the important genetic profiling information required for the successful execution of this clinical trial,” said Paul Kinnon, President and Chief Executive Officer of Transgenomic. “This is a key example of how Transgenomic works with pharmaceutical companies to employ complementary genetic tests designed to improve clinical diagnoses and outcomes.”
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
How Do Plants Avoid UV Damage?News
Public health warnings against too much exposure to UV are based on sound advice: UV rays can damage DNA and cause cancers and other diseases. Plants, however, cannot avoid UV. A new study now shows how plants' DNA repair system helps combat constant UV exposure.READ MORE
Comments | 0 ADD COMMENT
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018